<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04873180</url>
  </required_header>
  <id_info>
    <org_study_id>Soh-Med-21-04-28</org_study_id>
    <nct_id>NCT04873180</nct_id>
  </id_info>
  <brief_title>Significance of Immunohistochemical Expression of Survivin in Renal Cell Carcinoma</brief_title>
  <official_title>A Retrospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sohag University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sohag University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      detection of Survivin expression in renal cell carcinoma and correlate this expression to&#xD;
      tumor grade and stage.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      renal cell carcinoma is the third most prevalent malignant tumor of the genitourinary system.&#xD;
      deregulation of apoptosis is involved in carcinogenesis by abnormally prolonged cell&#xD;
      survival, facilitating accumulations of multiple mutations and augment resistance to&#xD;
      immune-surveillance. Survivin is a member of inhibitor of Apoptosis Protein family (IAPs). it&#xD;
      play a role in cell cycle regulation by inhibiting apiptosis. Survivin is over-expressed in&#xD;
      many human neoplasms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Actual">December 30, 2020</completion_date>
  <primary_completion_date type="Actual">June 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>expression of survivin in neoplastic and adjacent normal renal tissues</measure>
    <time_frame>april, 2021</time_frame>
    <description>Survivin is highly expressed in neoplastic renal tissues compared to normal ones by immunohistochemical measures..</description>
  </primary_outcome>
  <enrollment type="Actual">40</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>sectioning and staining of renal neoplasms after nephrectomy operation</intervention_name>
    <description>nephrectomy operations will be done to patients diagnosed as having renel tumors</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      tissue sections from cases of renal tumors will be preserved in formalin fixed, parraffin&#xD;
      embedded blocks.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with symptoms and signs of renal neoplasms admitted to Sohag University hospital&#xD;
        and underwent nephrectomy operations. excisional specimens sent to pathology Lab will be&#xD;
        sectioned and stained by H&amp;E. only cases of renal cell carcinoma will be included in the&#xD;
        study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients suffer from renal cell carcinomas&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients received pre-operative chemotherapy or radiotherapy. patients with&#xD;
             insufficient clinical data.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maisa H Mohammed, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>a lecturer of pathology, Sohag faculty of medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maisa Hashem Mohammed</name>
      <address>
        <city>Sohag</city>
        <zip>82524</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 30, 2021</study_first_submitted>
  <study_first_submitted_qc>April 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2021</study_first_posted>
  <last_update_submitted>May 5, 2021</last_update_submitted>
  <last_update_submitted_qc>May 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sohag University</investigator_affiliation>
    <investigator_full_name>Maisa Hashem Mohammed</investigator_full_name>
    <investigator_title>lecturer of pathology</investigator_title>
  </responsible_party>
  <keyword>Renal Cell Carcinoma</keyword>
  <keyword>Survivin</keyword>
  <keyword>Immnuohistochemistry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

